Elongin (SIII) Complex: A Potential Drug Target and Biomarker

Target Name: Elongin (SIII) complex

NCBI ID: P17630

Elongin (SIII) complex

Other Name(s): Elongin

Elongin (SIII) Complex: A Potential Drug Target and Biomarker

Introduction

The Elongin (SIII) complex is a protein that plays a crucial role in various cellular processes. It is a subunit of the enzyme elongin, which is responsible for the repetitive synthesis of DNA sequences at the ends of chromosome linears. of two subunits, Elongin A (also known as SSB1) and Elongin B (also known as SSB2), which are held together by a disulfide bond.

The Elongin complex has been extensively studied for its role in the regulation of DNA replication, repair, and transcription. It is well established that Elongin is involved in the repair of DNA double-strand breaks and has been shown to play a critical role in the rescue of DNA double-strand breaks in cells.

In recent years, scientists have discovered a number of drug targets and biomarkers related to Elongin. These findings raise potential interest in elongin in pharmaceutical and biomedical research. This article will explore the role of elongin, its potential as a drug target or biomarker, and discuss future directions for its research.

The role of Elongin

Elongin is a key enzyme in DNA double-strand repair. In the case of DNA double-strand breaks, elongin is able to recognize and repair the break. In this way, elongin prevents cells from being able to survive and reproduce in the presence of DNA double-strand breaks.

In addition, elongin is involved in many processes related to DNA replication and transcription. For example, elongin can bind to DNA polymerase and participate in DNA replication; at the same time, it can also bind to RNA polymerase and participate in the transcription process. These functions make elongin an important target for studying DNA replication and transcription.

as a drug target

Currently, a variety of drugs have been developed and used to treat diseases related to DNA double-strand repair. However, these drugs have certain limitations in terms of therapeutic efficacy and safety. Therefore, researchers are always looking for more effective drugs.

As an important enzyme, elongin can be used as a drug target to develop new drugs. Since elongin plays an important role in DNA double-strand repair, developing drugs that interfere with elongin function may be an effective treatment.

as biomarkers

Elongin may also serve as a biomarker to detect disease progression. For example, after cancer treatment, a patient's response can be assessed by measuring changes in elongin levels. In addition, elongin can also be used as a reliable indicator to evaluate DNA double-strand repair function.

future direction

With the deepening of research, we will have a deeper understanding of elongin's role and potential as a drug target or biomarker in the future. At the same time, researchers will continue to work hard to develop new drugs to treat diseases related to DNA double-strand repair.

in conclusion

Elongin is a very important enzyme that plays an important role in DNA double-strand repair and transcription. By developing new drugs and biomarkers, we can better understand elongin's effects and treat related diseases.

Protein Name: Elongin (SIII) Complex

The "Elongin (SIII) complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Elongin (SIII) complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets